Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2003

View Archived Issues

Sertraline reported to improve major depression in patients with AD

Sepracor updates status of key clinical development programs

New factor XIIIa inhibitors prepared and tested at Curacyte

Antimitotic drugs in early development at Pfizer

Sumitomo presents new 5-HT reuptake inhibitors/5-HT1A agonists

Novel peripheral BZ receptor ligands with neurotrophic activity claimed by Sanofi-Synthelabo

SCRAS scientists design new inhibitors of protein phosphatases

Radiolabeled Ab fragments and their use as angiogenesis markers in cancer diagnosis and treatment

Neurogen updates pipeline status

Abbott and LigoCyte enter collaboration for antiinflammatory monoclonal antibody

Preliminary PRIMO-CABG results reported

Allos Therapeutics commences rolling NDA submission for RSR-13

Norak acquires ChemFolio compound library

ISTA files second Vitrase NDA

Collaborative Study Group to conduct KRX-101 phase II/III program

Prana selects PBT-2 for development for Alzheimer's disease

New phase II trial evaluates NicVAX in smokers

aaiPharma and CIMA to merge

Small-molecule inhibitors of c-Met pursued at Sugen as potential anticancer agents

Lilly to use Serenex chemoproteomics technologies for screening

Bimosiamose decreases LAR in asthmatics following allergen challenge

Genome Therapeutics expands ramoplanin development program

Design of dual Src/Abl tyrosine kinase inhibitors with antitumor and antimetastatic activity

New agent with dual radiosensitizing and cytotoxic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...